Floatz logo

Atezolizumab

Gallbladder Adenocarcinoma

Georgetown Universitymonoclonal_antibodyPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Gallbladder Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Georgetown University
Phase 3BB
Bortezomib
National Cancer Institute (NCI)
Phase 2CCC
azd6244
National Cancer Institute (NCI)
Phase 2CCC
mk-2206
National Cancer Institute (NCI)
Phase 2CCC
CIS-DIAMMINEDICHLOROPLATINUM II
University of Nebraska
Phase 1CC

View all 14 →

Same molecule, other indications

Atezolizumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Stage IV Lung Cancer AJCC v8Dormant
BB
Indicative ·
70 / 100
View asset →
Her2-receptor negative breast cancerDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →